Bristol-Myers Squibb Company PFD CONV 2
BMYMP
Other OTC400.00
USD
-540.22
- -
CIK
0000014272
ISIN
US1101222073
Return %
Stock
S&P500
1Y
-46.81
26.53
3Y
-65.22
76.60
5Y
-65.22
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christopher S. Boerner
- Full Time Employees
- 34,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Princeton DE United States of America
- IPO Date
- Dec 8, 2003
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company is a global biopharmaceutical company engaged in discovering, developing, and delivering innovative medicines to treat serious diseases, with a focus on oncology, immunology, cardiovascular, and fibrosis segments. The company’s main products include cancer therapies such as Opdivo (nivolumab), Yervoy (ipilimumab), Abraxane, Empliciti, Abecma, and Krazati (adagrasib); cardiovascular drugs like Eliquis (apixaban) and Reblozyl; immunology and inflammation treatments including Orencia (abatacept) and Sotyktu; and therapies for multiple myeloma such as Revlimid and Pomalyst. It markets these products globally, serving a diverse patient population across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1887 and headquartered in New York City, Bristol-Myers Squibb has recently made several significant advances to strengthen and diversify its pipeline and product offerings. In early 2024, the company completed the acquisition of Mirati Therapeutics, adding the commercial lung cancer drug Krazati and expanding its oncology portfolio with promising clinical assets focused on KRAS and PRMT5 inhibitors. In 2025, Bristol-Myers Squibb announced its acquisition of Orbital Therapeutics for $1.5 billion, enhancing its cell therapy capabilities with next-generation CAR T-cell therapy candidates and proprietary RNA technology. The company has also launched new treatments such as Augtyrzo for ROS1-positive non-small cell lung cancer, Sotyktu for moderate-to-severe plaque psoriasis, and continues to expand indications for its established products. Additionally, it raised its 2025 revenue guidance due to accelerated growth from new product launches and strategic partnerships. Bristol-Myers Squibb operates multiple subsidiaries and leverages global strategic alliances to innovate and commercialize therapies across major and niche disease areas. Its portfolio spans branded prescription pharmaceuticals, advanced biologics, and cell therapies, positioning it as a leader in the global biopharma industry. The company continues to focus on broadening its oncological and immunological therapies while advancing cutting-edge modalities like cell and gene therapies, supporting its business expansion and revenue growth objectives. This comprehensive profile characterizes Bristol-Myers Squibb as a foremost global biopharmaceutical company with a diverse product portfolio, recent transformative acquisitions, and a growing pipeline that address serious diseases worldwide. It remains headquartered in New York City and demonstrates strategic agility through targeted acquisitions and innovative launches to maintain competitive advantage in the pharmaceutical sector.